Company Overview of Mayne Pharma (USA), Inc.
Mayne Pharma (USA), Inc. offers pharmaceutical products and services. The company focuses on two business segments including contract pharmaceutical services and development and manufacturing of branded and generic pharmaceutical products. Additionally, it provides pharmaceutical formulation development; first-time-in-man formulations; clinical trial material manufacturing for phase I, II, and III trials; and analytical method development and validation services. Mayne Pharma (USA), Inc. was formerly known as Faulding Pharmaceuticals Co. and changed its name to Mayne Pharma (USA), Inc. in December 2003. The company was founded in 1995 and is based in Paramus, New Jersey. Mayne Pharma (USA), ...
650 From Road
Mack Cali Centre II
Paramus, NJ 07652
Founded in 1995
Key Executives for Mayne Pharma (USA), Inc.
Group Chief Executive Officer
National Accounts Director of Southern Region
Director of Trade Relations
Compensation as of Fiscal Year 2015.
Mayne Pharma (USA), Inc. Key Developments
Mayne Pharma Names Q. Dwight Lewis as Vice President of Quality for U.S. Operations
Oct 22 14
Mayne Pharma has appointed Q. Dwight Lewis as vice president of quality for its operations in the United States. Lewis is responsible for managing all quality-related functions to ensure that Mayne Pharma’s U.S. pharmaceutical operations – which range from laboratories to manufacturing lines – continue to comply with global regulatory agency and industry standards. Before joining Mayne Pharma, Lewis was senior director of quality for Teva Pharmaceuticals, where he managed quality assurance and control functions for solid dose manufacturing. Prior to that, he served as vice president of quality for Irix Pharmaceuticals, and as director of quality operations for DSM Pharmaceuticals. Lewis brings to his new role expertise in new chemical entity (NCE) development, active pharmaceutical ingredient (API) and solid dose form manufacturing, generic product development, and contract services.
Mayne Pharma Group Limited Appoints Stefan Cross as President of Mayne Pharma USA
Jan 30 14
Mayne Pharma Group Limited has named Stefan Cross as President of Mayne Pharma USA. Cross is responsible for leading all of Mayne Pharma's existing business operations in the United States, and for spearheading new business development initiatives. Among those responsibilities includes managing the continued growth of contract pharmaceutical services as provided by Mayne Pharma's subsidiary, Metrics Inc. To that end, the company plans to make significant investments in Metrics' fast-track, proof-of-concept, and first-time-in-man programs, potent and cytotoxic product handling, and clinical trial material manufacturing for contract services clients. Cross also will oversee the expansion of Mayne Pharma USA's pharmaceutical products division, which has been one of the fastest-growing U.S. generics businesses in recent years. Cross will focus on expanding the U.S. product portfolio through both organic development and further bolt-on acquisitions. Prior to this most recent promotion, Cross served as Mayne Pharma's vice president of business and corporate development, and played a key role in the global commercialization of the company's SUBACAP anti-fungal product. Cross brings more than 20 years of industry experience to his role. He previously headed marketing efforts in the Asia Pacific region for Hospira Inc. Cross succeeds Phil Hodges, who founded Metrics Inc. almost two decades ago and recently retired as president of the company. Hodges serves on the board of directors of Mayne Pharma Group Limited.
Mayne Pharma (USA), Inc. Announces Executive Changes
Sep 5 13
Mayne Pharma Group Limited has appointed Mr. Stefan Cross as President of Mayne Pharma USA, effective from November 2013. Mr. Cross will be responsible for leading Mayne Pharma s US business operations which include US Generic Products and Metrics Contract Services, together with other US business development initiatives. Mr. Cross is currently Vice President, Business and Corporate Development and has played a leading role in the commercialisation of SUBACAP globally. He has also been extensively involved in the integration of Metrics and executing the Company s business strategy both in Australia and the US since he joined the business in 2012. Stefan will succeed Phil Hodges. Phil will be stepping down as planned from his executive responsibilities at the end of December 2013 but will continue to be a director of Mayne Pharma Group Limited and provide ongoing advice to ensure a smooth leadership transition.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|